Oncodesign announces EUR 10 million funding for oncology biomarker program IMAkinib
Oncodesign announced that French innovation agency, OSEO, will provide more than 40 percent of the funding for the IMAkinib program, aimed at oncology biomarker development. The total cost of the program will be around EUR 24.7 million over eight years. Oncodesign heads the project in collaboration with two partners: Guerbet for the development of radiotracers and clinical trials for the biomarkers and Ariana Pharmaceuticals for the analysis of chemical and biological data.
"The development will take place while we work on lead optimization programs for kinase inhibitors for our pharmaceutical customers," said Philippe Genne, Oncodesign CEO. "This synergy has the added advantage of benefiting our customers while we work on biomarkers adapted to the clinical environment and to the prescription of their therapies. IMAkinib means that Oncodesign will be clearly positioned on the drug discovery and pharmaco-imaging biomarker markets. The program will be a cornerstone of our strategy, which we started a year ago, to become a key player in therapeutic and diagnostic oncology discovery over the next three years."
The OSEO financing comes as part of France's ISI program for strategic industrial innovation (Innovation Stratégique Industrielle). ISI aims are to foster the emergence of European or global champions.
Most read news
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Watching complex molecules at work
GE Healthcare and BAC start collaboration in biopharmaceutical purification
Oxford Medical Diagnostics and Michell Instruments launch gas analysis partnership - Oxford Medical Diagnostics and Michell Instruments will jointly develop new industrial gas detection and measurement devices for a number of industrial applications
Wiley InterScience Launches the Analytical Sciences Backfile Collection
Eurofins expands food and feed testing business in the US
QIAGEN launches coronavirus test kit in Germany following derogation by BfArM
Unexpected flexibility found in odorant molecules - High resolution rotational spectroscopy reveals an unprecedented number of conformations of an odorant molecule – a new world record!
How environmental changes affect the shapes of RNA in living cells - Results raises the possibility that we may use this knowledge to fine-tune crops or develop RNA-based therapies for diseases such as COVID-19
New analysis of the structure of silks explains paradox of super-strength - Could lead to even stronger synthetic materials
Verder Group acquires specialist for particle characterization